登革热疫苗卫生经济学评价的系统综述
该系统综述检索多个数据库,纳入13项登革热疫苗卫生经济学评价研究,均来自亚洲和拉丁美洲国家。所有研究均支持引入疫苗,但方法学报告不足,多数研究CHEERS清单报告率低于55%,成本效果结果不宜直接外推至其他国家。
要点
- 13项登革热疫苗经济学评价均支持疫苗引入,但方法学报告质量普遍不足。
- 8/13项研究CHEERS清单报告率不足55%,影响结果可靠性。
- 疫苗效力、安全性、保护时长等假设及模型选择影响研究有效性。
核心结论
- 登革热疫苗经济学评价未遵循推荐的一般方法,成本效果结果不应转移至其他国家。
研究设计与样本
- 系统检索MEDLINE、EMBASE、SCOPUS、NHS EED、HTA Database和LILACS数据库,纳入登革热疫苗完整卫生经济学评价研究。
- 由两名独立评审员筛选文献并提取数据,采用CHEERS清单评估报告质量,进行定性叙述性综合。
主要发现
- 共纳入13项在亚洲和拉丁美洲国家开展的研究,所有研究均对疫苗引入持有利态度。
- 疫苗效力、安全性、保护时长等假设及研究人群和模型类型的选择,加上方法学步骤报告不足,影响结果有效性。
- 8/13项研究报告的CHEERS清单条目不足55%。
临床怎么用
- 建议使用本地流行病学和成本数据开展经济学评价,疫苗假设应反映临床试验观察结果。
局限性
- 纳入研究的方法学报告质量不足,可能影响结果可靠性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To review the literature on economic evaluation of dengue vaccination to produce evidence to support a local cost-effectiveness study and to subsidize the decision to introduce a dengue vaccine in the Brazilian National Immunization Program. METHODS: We systematically searched multiple databases (MEDLINE (via PubMed), EMBASE, SCOPUS, NHS Economic Evaluation Database (NHS EED), HTA Database (via Centre for Reviews and Dissemination - CRD) and LILACS), selecting full HEEs of dengue vaccine. Two independent reviewers screened articles for relevance and extracted the data. The methodology for the quality reporting was assessed using CHEERS checklist. We performed a qualitative narrative synthesis. RESULTS: Thirteen studies conducted in Asian and Latin America countries were reviewed. All studies were favorable to the incorporation of the vaccine. However, the assumptions and values assumed for vaccine efficacy, safety and duration of protection, as well as the choice of the study population and the type of model used in the analyses, associated to an insufficient reporting of the methodological steps, affect the validity of the studies' results. The quality reporting appraisal showed that the majority (8/13) of the studies reported less than 55% of the CHEERS checklists' items. CONCLUSIONS: This systematic review shows that the economic evaluation of dengue vaccination did not adhere to key recommended general methods for economic evaluation. The presented cost-effectiveness results should not be transferred to other countries. It is recommended to conduct studies with local epidemiological and cost data, as well as assumptions about vaccination that reflect the results observed in clinical trials.
引用
- de Soárez PC, Silva AB, Randi BA, et al. Systematic review of health economic evaluation studies of dengue vaccines. Vaccine. 2019. PMID: 30910406. doi:10.1016/j.vaccine.2019.03.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。